Cornerstone laid for new Pharmaceutical Development sterile pilot plant at Novartis site in Stein
Speaking at the event, Michael Plüss, Head of Novartis Switzerland, commented: "Our investment of over CHF 150 million indicates that the Basel region will remain the most important location for Novartis in the future. The conditions for the pharmaceutical industry are ideal here, and we see our excellent partnership with the local authorities as a hugely important positive point."
The new plant is scheduled for completion in 2008. To ensure that supplies of the required sterile dosage forms continue uninterrupted, operations will be relocated as the new equipment is brought on stream in several stages between 2007 and 2008. During this period, between 30 and 40 people will start working at the new plant in Stein.
Designed as a multifunctional production center, the new plant will make it possible for more - and more complex - dosage forms to be manufactured than in the past. As Armin Meinzer, Head of Technical R&D, explained: "Innovative active substances are becoming increasingly important in our pipeline, thanks not only to our own compounds but also to new collaborative ventures with biotech companies; accordingly, we need to expand our capacity and flexibility for the production of sterile dosage forms for clinical trials." Altogether, the new plant will permit the manufacture of twice as many sterile products as current facilities.
Most read news
Other news from the department manufacturing
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.